Forskning ved Københavns Universitet - Københavns Universitet

Forside

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. / Balas, Bogdan; Baig, Muhammad R; Watson, Catherine; Dunning, Beth E; Ligueros-Saylan, Monica; Wang, Yibin; He, Yan-Ling; Darland, Celia; Holst, Jens J; Deacon, Carolyn F; Cusi, Kenneth; Mari, Andrea; Foley, James E; DeFronzo, Ralph A.

I: Journal of Clinical Endocrinology and Metabolism, Bind 92, Nr. 4, 2007, s. 1249-55.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Balas, B, Baig, MR, Watson, C, Dunning, BE, Ligueros-Saylan, M, Wang, Y, He, Y-L, Darland, C, Holst, JJ, Deacon, CF, Cusi, K, Mari, A, Foley, JE & DeFronzo, RA 2007, 'The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.', Journal of Clinical Endocrinology and Metabolism, bind 92, nr. 4, s. 1249-55. https://doi.org/10.1210/jc.2006-1882

APA

Balas, B., Baig, M. R., Watson, C., Dunning, B. E., Ligueros-Saylan, M., Wang, Y., ... DeFronzo, R. A. (2007). The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism, 92(4), 1249-55. https://doi.org/10.1210/jc.2006-1882

Vancouver

Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y o.a. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism. 2007;92(4):1249-55. https://doi.org/10.1210/jc.2006-1882

Author

Balas, Bogdan ; Baig, Muhammad R ; Watson, Catherine ; Dunning, Beth E ; Ligueros-Saylan, Monica ; Wang, Yibin ; He, Yan-Ling ; Darland, Celia ; Holst, Jens J ; Deacon, Carolyn F ; Cusi, Kenneth ; Mari, Andrea ; Foley, James E ; DeFronzo, Ralph A. / The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. I: Journal of Clinical Endocrinology and Metabolism. 2007 ; Bind 92, Nr. 4. s. 1249-55.

Bibtex

@article{a7802b60ab4911ddb5e9000ea68e967b,
title = "The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.",
abstract = "AIMS/HYPOTHESIS: Vildagliptin is a selective dipeptidyl peptidase IV inhibitor that augments meal-stimulated levels of biologically active glucagon-like peptide-1. Chronic vildagliptin treatment decreases postprandial glucose levels and reduces hemoglobin A1c in type 2 diabetic patients. However, little is known about the mechanism(s) by which vildagliptin promotes reduction in plasma glucose concentration. METHODS: Sixteen patients with type 2 diabetes (age, 48+/-3 yr; body mass index, 34.4+/-1.7 kg/m2; hemoglobin A1c, 9.0+/-0.3{\%}) participated in a randomized, double-blind, placebo-controlled trial. On separate days patients received 100 mg vildagliptin or placebo at 1730 h followed 30 min later by a meal tolerance test (MTT) performed with double tracer technique (3-(3)H-glucose iv and 1-(14)C-glucose orally). RESULTS: After vildagliptin, suppression of endogenous glucose production (EGP) during 6-h MTT was greater than with placebo (1.02+/-0.06 vs. 0.74+/-0.06 mg.kg-1.min-1; P=0.004), and insulin secretion rate increased by 21{\%} (P=0.003) despite significant reduction in mean plasma glucose (213+/-4 vs. 230+/-4 mg/dl; P=0.006). Consequently, insulin secretion rate (area under the curve) divided by plasma glucose (area under the curve) increased by 29{\%} (P=0.01). Suppression of plasma glucagon during MTT was 5-fold greater with vildagliptin (P<0.02). The decline in EGP was positively correlated (r=0.55; P<0.03) with the decrease in fasting plasma glucose (change=-14 mg/dl). CONCLUSIONS: During MTT, vildagliptin augments insulin secretion and inhibits glucagon release, leading to enhanced suppression of EGP. During the postprandial period, a single dose of vildagliptin reduced plasma glucose levels by enhancing suppression of EGP.",
author = "Bogdan Balas and Baig, {Muhammad R} and Catherine Watson and Dunning, {Beth E} and Monica Ligueros-Saylan and Yibin Wang and Yan-Ling He and Celia Darland and Holst, {Jens J} and Deacon, {Carolyn F} and Kenneth Cusi and Andrea Mari and Foley, {James E} and DeFronzo, {Ralph A}",
note = "Keywords: Adamantane; Adenosine Deaminase; Antigens, CD26; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Enzyme Inhibitors; Female; Glucose; Glycoproteins; Hemoglobin A, Glycosylated; Humans; Hypoglycemic Agents; Islets of Langerhans; Kinetics; Male; Middle Aged; Nitriles; Obesity; Pyrrolidines",
year = "2007",
doi = "10.1210/jc.2006-1882",
language = "English",
volume = "92",
pages = "1249--55",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "Oxford University Press",
number = "4",

}

RIS

TY - JOUR

T1 - The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

AU - Balas, Bogdan

AU - Baig, Muhammad R

AU - Watson, Catherine

AU - Dunning, Beth E

AU - Ligueros-Saylan, Monica

AU - Wang, Yibin

AU - He, Yan-Ling

AU - Darland, Celia

AU - Holst, Jens J

AU - Deacon, Carolyn F

AU - Cusi, Kenneth

AU - Mari, Andrea

AU - Foley, James E

AU - DeFronzo, Ralph A

N1 - Keywords: Adamantane; Adenosine Deaminase; Antigens, CD26; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Enzyme Inhibitors; Female; Glucose; Glycoproteins; Hemoglobin A, Glycosylated; Humans; Hypoglycemic Agents; Islets of Langerhans; Kinetics; Male; Middle Aged; Nitriles; Obesity; Pyrrolidines

PY - 2007

Y1 - 2007

N2 - AIMS/HYPOTHESIS: Vildagliptin is a selective dipeptidyl peptidase IV inhibitor that augments meal-stimulated levels of biologically active glucagon-like peptide-1. Chronic vildagliptin treatment decreases postprandial glucose levels and reduces hemoglobin A1c in type 2 diabetic patients. However, little is known about the mechanism(s) by which vildagliptin promotes reduction in plasma glucose concentration. METHODS: Sixteen patients with type 2 diabetes (age, 48+/-3 yr; body mass index, 34.4+/-1.7 kg/m2; hemoglobin A1c, 9.0+/-0.3%) participated in a randomized, double-blind, placebo-controlled trial. On separate days patients received 100 mg vildagliptin or placebo at 1730 h followed 30 min later by a meal tolerance test (MTT) performed with double tracer technique (3-(3)H-glucose iv and 1-(14)C-glucose orally). RESULTS: After vildagliptin, suppression of endogenous glucose production (EGP) during 6-h MTT was greater than with placebo (1.02+/-0.06 vs. 0.74+/-0.06 mg.kg-1.min-1; P=0.004), and insulin secretion rate increased by 21% (P=0.003) despite significant reduction in mean plasma glucose (213+/-4 vs. 230+/-4 mg/dl; P=0.006). Consequently, insulin secretion rate (area under the curve) divided by plasma glucose (area under the curve) increased by 29% (P=0.01). Suppression of plasma glucagon during MTT was 5-fold greater with vildagliptin (P<0.02). The decline in EGP was positively correlated (r=0.55; P<0.03) with the decrease in fasting plasma glucose (change=-14 mg/dl). CONCLUSIONS: During MTT, vildagliptin augments insulin secretion and inhibits glucagon release, leading to enhanced suppression of EGP. During the postprandial period, a single dose of vildagliptin reduced plasma glucose levels by enhancing suppression of EGP.

AB - AIMS/HYPOTHESIS: Vildagliptin is a selective dipeptidyl peptidase IV inhibitor that augments meal-stimulated levels of biologically active glucagon-like peptide-1. Chronic vildagliptin treatment decreases postprandial glucose levels and reduces hemoglobin A1c in type 2 diabetic patients. However, little is known about the mechanism(s) by which vildagliptin promotes reduction in plasma glucose concentration. METHODS: Sixteen patients with type 2 diabetes (age, 48+/-3 yr; body mass index, 34.4+/-1.7 kg/m2; hemoglobin A1c, 9.0+/-0.3%) participated in a randomized, double-blind, placebo-controlled trial. On separate days patients received 100 mg vildagliptin or placebo at 1730 h followed 30 min later by a meal tolerance test (MTT) performed with double tracer technique (3-(3)H-glucose iv and 1-(14)C-glucose orally). RESULTS: After vildagliptin, suppression of endogenous glucose production (EGP) during 6-h MTT was greater than with placebo (1.02+/-0.06 vs. 0.74+/-0.06 mg.kg-1.min-1; P=0.004), and insulin secretion rate increased by 21% (P=0.003) despite significant reduction in mean plasma glucose (213+/-4 vs. 230+/-4 mg/dl; P=0.006). Consequently, insulin secretion rate (area under the curve) divided by plasma glucose (area under the curve) increased by 29% (P=0.01). Suppression of plasma glucagon during MTT was 5-fold greater with vildagliptin (P<0.02). The decline in EGP was positively correlated (r=0.55; P<0.03) with the decrease in fasting plasma glucose (change=-14 mg/dl). CONCLUSIONS: During MTT, vildagliptin augments insulin secretion and inhibits glucagon release, leading to enhanced suppression of EGP. During the postprandial period, a single dose of vildagliptin reduced plasma glucose levels by enhancing suppression of EGP.

U2 - 10.1210/jc.2006-1882

DO - 10.1210/jc.2006-1882

M3 - Journal article

C2 - 17244786

VL - 92

SP - 1249

EP - 1255

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -

ID: 8416966